Recently, sirolimus-eluting stents implantation has been shown to decrease restenosis markedly in selected patients. Nonetheless, the effects of SES implantation in complex, unselected patients, such as those commonly treated in daily practice ('the real world'), remains largely unknown. This book comprehensively evaluates the impact of SES implantation on the outcomes of patients treated in the real world of
interventional cardiology. The authors have evaluated in detail the short- and
long-term outcomes of several high-risk subsets not currently included in randomized trials. While it is specific to sirolimus, the book covers the major competing
drug eluting stents, including paclitaxel.
